BILL ANALYSIS

Senate Research Center	H.B. 428
87R1235 SMT-D	By: King, Ken et al. (Zaffirini)
	Business & Commerce
	5/15/2021
	Engrossed

AUTHOR'S / SPONSOR'S STATEMENT OF INTENT

The five-year survival rate for persons diagnosed with ovarian cancer is less than 50 percent. Accordingly, early detection is essential to increasing women's chances at defeating the disease. H.B. 428 would include any test or screening approved by the Food and Drug Administration for the detection of ovarian cancer among required coverage during annual well woman examinations.

H.B. 428 amends current law relating to health benefit plan coverage for ovarian cancer testing and screening.

RULEMAKING AUTHORITY

This bill does not expressly grant any additional rulemaking authority to a state officer, institution, or agency.

SECTION BY SECTION ANALYSIS

SECTION 1. Amends Section 1370.003(b), Insurance Code, to provide that coverage required under Section 1370.003 (Coverage Required) includes at a minimum certain tests, including any test or screening approved by the United States Food and Drug Administration for the detection of ovarian cancer. Makes nonsubstantive changes.

SECTION 2. Provides that Section 1370.003, Insurance Code, as amended by this Act, applies only to a health benefit plan delivered, issued for delivery, or renewed on or after January 1, 2022. Provides that a health benefit plan delivered, issued for delivery, or renewed before January 1, 2022, is governed by the law as it existed immediately before the effective date of this Act, and that law is continued in effect for that purpose.

SECTION 3. Effective date: September 1, 2021.